Alkermes forges $950M biotech buyout deal in a bold bet on an early-stage CNS drug platform
Alkermes $ALKS is investing $100 million cash and committing up to $850 million more in milestones in a big wager on a very early-stage CNS discovery platform. And the biotech is adding $20 million more to fund next year’s new research work on the platform it’s acquiring in today’s buyout with an eye to expanding the research work in oncology.
The biotech, helmed by Richard Pops, is buying Rodin Therapeutics, which had focused early on Alzheimer’s disease. Pops’ buyout, though, isn’t focused solely on the most troublesome sector in pharma R&D.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.